title: GMDP augments antitumor action of the CP/TNFalpha combination in vivo.
abstract: We have shown that glucosaminyl muramyl dipeptide (GMDP) has been augmented the antitumor action of chemotherapy drug cisplatin and tumor necrosis factor-alpha (TNFalpha) on the Ehrlich ascites carcinoma and melanoma B-16 mouse tumor models. The doses of cisplatin, TNFalpha and GMDP and also the conditions of the drugs combination injection provided 100% survival of mice with Ehrlich ascites carcinoma were found. Furthermore, it was shown first that GMDP has been decreased toxicity of the cisplatin/TNFalpha combination and normalized the changes in the experimental mice hematological parameters which were produced by the CP/TNFalpha combination.
authors.affiliation: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10, Mikhlukho-Macklaya street, Moscow 117997, Russian Federation. petrova@ibch.ru
authors.forename: Elena E
authors.initials: EE
authors.lastname: Petrova
authors.forename: Maria A
authors.initials: MA
authors.lastname: Simonova
authors.forename: Ravilya L
authors.initials: RL
authors.lastname: Komaleva
authors.forename: Marina V
authors.initials: MV
authors.lastname: Britsina
authors.forename: Tatiana M
authors.initials: TM
authors.lastname: Andronova
authors.forename: Vladimir A
authors.initials: VA
authors.lastname: Nesmeyanov
authors.forename: Tatiana I
authors.initials: TI
authors.lastname: Valyakina
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013534:Survival; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine; D002945:Cisplatin